Paliperidone Teva (Paliperidone Palmitate)

Paliperidone palmitate is a dopamine‑serotonin antagonist used in chronic psychotic disorders.

• Schizophrenia: maintenance therapy to reduce relapse and control psychotic symptoms.
• Schizoaffective disorder: management of psychotic features alongside mood symptoms.
• Maintenance after acute episode: provides sustained drug levels to support long‑term stability.

• Paliperidone palmitate exerts its antipsychotic effect by antagonizing dopamine D2 receptors and serotonin 5‑HT2A receptors in the central nervous system, thereby modulating neurotransmission linked to psychosis. The long‑acting formulation releases the active moiety slowly after intramuscular injection, maintaining therapeutic plasma concentrations for up to a month.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Weight gain: gradual increase in body weight.
• Akathisia: inner restlessness or inability to stay still.
• Drowsiness: somnolence or reduced alertness.
• Constipation: decreased bowel movements.
• Elevated prolactin: hormonal changes leading to menstrual disturbances or galactorrhea.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: persistent involuntary movements.
• Seizures: increased risk in susceptible individuals.
• Orthostatic hypotension: sudden drop in blood pressure upon standing.
• Hyperglycemia: elevated blood glucose levels.
• Cardiovascular events: arrhythmias or myocardial infarction.

Before initiating therapy with Paliperidone Teva, clinicians should evaluate patient history and monitor for specific risks.

• Cardiovascular disease: assess for history of arrhythmias or heart failure.
• Metabolic disorders: monitor weight, glucose, and lipid profiles regularly.
• Pregnancy: avoid use unless benefits outweigh potential fetal risks.
• Breastfeeding: contraindicated as drug is excreted in milk.
• Elderly patients: start at lower dose and observe for orthostatic hypotension.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone palmitate can interact with several medication classes, altering efficacy or safety.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase paliperidone levels and toxicity.
• CNS depressants (e.g., benzodiazepines): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., carbamazepine): may reduce drug exposure, risking loss of efficacy.

• Antihypertensives: additive orthostatic hypotension may occur.
• Anticholinergic agents: may exacerbate cognitive side effects.